person · Reporting owner
Ralls-Morrison Desiree
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP, GC and Corp Secretary | February 21, 2021 | February 23, 2021 |
| DICK'S SPORTING GOODS, INC.DKS · Entity 556 | Director | June 10, 2026 | June 12, 2026 |
| MCDONALDS CORPMCD · Entity 2849 | EVP, Chief Legal Officer | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 21, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,909 |
Ending reported balance
After 2021-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-21 · Exercise / conversion · Acquired 1,324 · Balance 30,298 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2021-02-21 · Tax withholding · Disposed 389 · Balance 29,909 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-02-21 | Direct | 2,648 |
Reported balance
After 2021-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-21 · Exercise / conversion · Disposed 1,324 · Balance 2,648 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. |
| Performance Share UnitsSEC Table II · derivative / convertible security · Expires 2022-12-31 | Direct | 6,041 |
Reported balance
After 2021-02-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-22 · Grant · Acquired 6,041 · Balance 6,041 F3: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
F3: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.
DICK'S SPORTING GOODS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 7,422 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 838 · Balance 7,422 F1: Represents restricted unit award granted on June 10, 2026. These units are subject to time-based vesting requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted unit award granted on June 10, 2026. These units are subject to time-based vesting requirements.
MCDONALDS CORP
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,268.12 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Sale · Disposed 2,763 · Balance 6,268.12 F1: This transaction was executed in multiple trades ranging from $277.60 to $280.19 per share. The price reported represents the weighted average sales price of this trade. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares sold at each separate price. |
| Phantom StockSEC Table II · derivative / convertible security | IndirectNon-Qualified Benefit Plan | 3,278.25 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,278.25 F2: Each share of phantom stock represents a right to receive the cash value of one share of the Company's common stock. F3: Shares of phantom stock are payable in cash following the reporting person's separation from service with the Company. F4: Includes shares acquired through dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades ranging from $277.60 to $280.19 per share. The price reported represents the weighted average sales price of this trade. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares sold at each separate price.
F2: Each share of phantom stock represents a right to receive the cash value of one share of the Company's common stock.
F3: Shares of phantom stock are payable in cash following the reporting person's separation from service with the Company.
F4: Includes shares acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2019 Filed Jan 10, 2019 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,047 | $36.00 | $145,692.00 |
DisclosureSEC source: 0001225208-19-000803 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,889 Underlying: Common Stock · 11,472 shares Expires 2022-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,379 | $37.67 | $127,286.93 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,679 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 16,685 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003401 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Underlying: Common Stock · 16,685 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 5,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003401 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,537 Underlying: Common Stock · 5,537 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:05 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 57,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018210 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,361 Underlying: Common Stock · 57,361 shares Expires 2022-12-01 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.